RightRep EN · PT Open the app
BLOG

Can You Train With Hypertrophic Cardiomyopathy? The Shared-Decision Audit: The Door Where Both of the Gym's Default Scripts — HCM Means a Barbell Can Stop Your Heart, So No Lifting Ever Again, and a Thick Heart in an Athlete Is Just Fitness, Push Through — Fail the Reader (the Registry Column: HCM Is the Single Most Common Cause of Sudden Death in Young Competitive Athletes at 36% of 1,049 Cardiovascular Deaths Across the 27-Year US Registry, 82% of Them During Exertion — an Average of 66 Athletes a Year Against Millions of Training Sessions; the Census Column: CARDIA's 4,111 Echocardiograms Found HCM in 0.17% of Ordinary 23-to-35-Year-Olds and Only 1 of Those 7 Had Ever Had a Cardiac Symptom — the Wild Population Is Mostly Undiagnosed and Already Training; the Ban-Era Column: the 2015 Task Force Excluded Athletes With HCM From Most Competitive Sports on Accumulated Expert Caution, Not on Exercise-Training Data; the RCT Column: the Michigan–Stanford Trial Randomized 136 Patients to 16 Weeks of Moderate-Intensity Exercise — Peak VO₂ Rose +1.27 mL/kg/min Between Groups With Zero Sustained Ventricular Arrhythmias, Zero Arrests, Zero Appropriate ICD Shocks and Zero Deaths in Either Arm; the Paradigm Column: the 2026 European Heart Journal File Reads the New Era — Low-Risk HCM Can Train, and Even Compete, 'in the Absence of Safety Signals,' on Individualized Goal-Oriented Prescriptions and Shared Decision-Making; the Guideline Column: the 2024 AHA/ACC Guideline and the 2020 ESC Sports-Cardiology Guideline Have Both Replaced the Blanket Ban With Individualized Exercise Counseling; the Brazilian Column: the Brazilian Society of Cardiology's Own 2026 Systematic Review — 8 Studies and 9,744 Participants With No Mortality or Severe-Arrhythmia Signal at Any Intensity, and Exercise 'Should Be Encouraged Based on Individualized Assessment'; the Risk-Marker Column: What Actually Predicts Events — Prior Arrest, Sustained VT, Exertional Syncope, Extreme Wall Thickness, Family History — Measured by Echo, Holter, MRI and Supervised Exercise Testing, Never by Feelings; the Differentiation Column: the Athlete's-Heart Gray Zone at 13–15 mm of Symmetric Wall, Regression With Detraining, and Why the Diagnosis Is Echo's to Make; the Mortality-Trend Column: US HCM Death Rates Fell 53% From 1999 to 2019, Steepest at −62% Among 15-to-24-Year-Olds — the Era the Fear Script Was Written In Is Over) — the Answer Is a Negotiated License: the Diagnosis Belongs to the Cardiologist, the Risk Stratification to the Measurements, and Inside the Fences the Training Itself Is Part of the Treatment

By RightRep AI Assistant · · 27 min read

Hypertrophic cardiomyopathy is the door where the internet's two default scripts — the fear script: HCM is the condition that kills young athletes, so a barbell can stop your heart, never lift again and the dismissive script: athlete's hearts are thick, yours is just trained, push through whatever you feel — both fail the reader at the exact door she walked in through, because this reader is one of three people: the one who fainted mid-session or mid-race and came back from cardiology holding the word hypertrophic cardiomyopathy and a browser full of stadium tragedies; the one whose echo report says asymmetric septal hypertrophy, 19 mm and who has not decided whether that sentence ends her training life; or the one whose family lost somebody at 30 and whose cardiologist now says her own echo is borderline, that the wall sits in the gray zone where training adaptation and disease overlap. The fear script fails because the blanket ban it quotes is a 2015 document written on accumulated expert caution, not on exercise-training data [3][4] — and because the first randomized trial of exercise in HCM put 136 patients through 16 weeks of moderate-intensity training and produced zero sustained ventricular arrhythmias, zero sudden cardiac arrests, zero appropriate ICD shocks and zero deaths in either arm, with peak VO₂ rising +1.27 mL/kg/min more than usual activity [6]; the Brazilian Society of Cardiology's own 2026 systematic review — 8 studies, 9,744 participants — found no increased mortality or severe arrhythmic events with exercise at any intensity, and concluded exercise "should be encouraged based on individualized assessment" [12]. The dismissive script fails because HCM is, honestly priced, the top of the athlete sudden-death registry — 36% of the 1,049 cardiovascular deaths among 1,866 US athletes over 27 years, 82% of them during exertion [8] — and because "your thick heart is probably just training" is a differential diagnosis made with an echocardiogram, a family history and sometimes an MRI, never with a comment section [10][11]. So the fences come first. First: the red-flag fence — anyone with exertional fainting or near-fainting, exertional chest pain, breathlessness out of proportion to the work, or a family history of sudden unexplained death before 50 is a cardiology appointment before the next session, not a deload; those are the exact sentences the screening door exists to catch [1][8][11]. Second: the diagnosed-without-a-plan fence — an HCM diagnosis without a cardiology exercise plan means no self-administered maximum efforts of any kind: no 1RM tests, no all-out metcons, no sprint intervals until the risk stratification (echo, Holter, exercise test, family file, and where indicated cardiac MRI) has actually been done [1][2]. Third: the high-risk fence — a prior cardiac arrest, sustained ventricular tachycardia, unexplained recent syncope, extreme wall thickness, or a strong family line of sudden death moves the conversation to an ICD and a specialist-defined bracket, and inside that bracket training still happens — it is prescribed, not improvised [1][11]. Fourth: the obstruction fence — the roughly third of patients whose left-ventricular outflow tract obstructs at rest (and the further third in whom it can be provoked) own the load-management chapter: dehydration, prolonged standing and heavy straining Valsalva all worsen obstruction, so maximal singles on an empty stomach at 6 a.m. are the exact wrong format until cleared [1][11]. Fifth: the family fence — HCM is genetic in most cases, first-degree relatives get offered screening, and the genotype-positive phenotype-negative relative trains under surveillance rather than under a ban [1][11]. With the fences standing, the file underneath is one of the strongest inversions in this library's cardiac wing: the answer is a negotiated license — the diagnosis belongs to the cardiologist, the risk stratification to the measurements, and inside the fences the training itself is part of the treatment [1][5][6][12].

The short answer: yes — a negotiated license, not a verdict

Strip the file to its spine. The registry column: HCM is the most common cardiovascular cause of sudden death in young competitive athletes — 1,866 US athlete deaths 1980–2006, 1,049 (56%) cardiovascular, HCM 36% of them against 17% for coronary anomalies, 82% during competition or training, 11% female [8]; the registry update through 2011 held the line — 302 of 842 autopsy-confirmed cardiovascular deaths (36%), 39% of male deaths versus 11% of female, 42% among Black athletes versus 31% among white [9]. The census column: CARDIA ran echocardiograms on 4,111 ordinary 23-to-35-year-olds and found probable or definite HCM in 7 (0.17%) — "about 2 of 1000 young adults" — of whom only one had ever had an important cardiac symptom [7]; the wild population is mostly undiagnosed and mostly already training. The ban-era column: the 2015 expert-consensus documents excluded athletes with probable or definite HCM from most competitive sports [3] — a policy the field itself came to audit, because the exclusion rested on expert opinion, not on exercise-training data [4]. The RCT column: Michigan and Stanford randomized 136 HCM patients (mean age 50.4, 42% women) to 16 weeks of moderate-intensity exercise training or usual activity — peak VO₂ +1.35 vs +0.08 mL/kg/min (between-group +1.27, 95% CI 0.17–2.37, P=.02), zero arrhythmic events of any severity in either arm [6]. The paradigm column: the 2026 European Heart Journal review reads the new era — observational studies and randomized trials show improved functional capacity, quality of life and cardiovascular and psychological health with tailored exercise, including competitive sports in low-risk individuals, "in the absence of safety signals," on individualized, goal-oriented prescriptions supported by shared decision-making [5]. The guideline column: the 2024 AHA/ACC guideline and the 2020 ESC sports-cardiology guideline have both replaced the blanket ban with individualized exercise counseling [1][2]. The Brazilian column: the SBC's own 2026 systematic review — 4 RCTs and 4 observational studies, 9,744 participants — found no mortality or severe-arrhythmia signal at moderate or even vigorous intensity, a Korean cohort of 7,000+ showing all-cause mortality falling as intensity rose (dose–response), and no severe adverse events in low-risk athletes competing [12]. The risk-marker column: what actually predicts events — prior arrest, sustained VT, exertional or unexplained syncope, severe hypertrophy, family history of sudden death, outflow obstruction at rest — is measured by echo, Holter, exercise testing and MRI, and the ICD exists to avert the risk in the high-risk subset [11]. The differentiation column: athlete's heart and HCM share a boundary at the thick wall — symmetric remodeling that regresses with detraining versus asymmetric disease that does not, with the 13–15 mm gray zone where only the full workup, not training history alone, can tell them apart [10]. The mortality-trend column: US HCM death rates fell 53% cumulatively from 1999 to 2019 — against 25% for non-HCM cardiovascular disease and 18% for all causes — steepest at −62% among 15-to-24-year-olds [14]. That is the audit in one paragraph: the fear is priced, the license is real, and the negotiation is done with measurements and a cardiologist — not with either script [1][5][6][12].

The registry column: why the fear script exists, priced honestly

The fear script has a real receipt, and this library's audits pay their debts by quoting it. Maron's US registry spent 27 years (1980–2006) systematically tracking sudden deaths in competitive athletes and identified 1,866 athletes who died suddenly or survived cardiac arrest, average age 19, across 38 sports; 1,049 (56%) were cardiovascular, blunt trauma caused 22%, commotio cordis 3%, heat stroke 2% [8]. And at the top of the cardiovascular list: hypertrophic cardiomyopathy, 36% — the single most common cause, ahead of congenital coronary anomalies at 17% [8]. The circumstances matter as much as the rank: 82% of the cardiovascular deaths occurred with physical exertion during competition or training, 54% were high-school students, and only 11% were female — though the female share rose over time [8]. The update through 2011 confirmed the structure: of 842 athletes with autopsy-confirmed cardiovascular diagnoses, HCM caused 302 deaths (36%) — 39% of male sudden deaths versus 11% of female, and more common among Black athletes (42%) than white (31%) [9]. Now price the denominator the fear script hides: the same registry counts an average of 66 cardiovascular athlete deaths per year over its final six years (range 50–76) [8] — against millions of training sessions, and against a condition that itself lives in roughly 2 of every 1,000 young adults [7]. Both things are true at once, and the door between them is exactly where this reader stands: HCM is the named killer of young athletes, and the absolute event it is feared for is rare enough that the field could hold a decade-long debate about whether the fear's prescription — total inactivity — was itself the harm [4][5]. The honest translation: the registry justifies the fences (screening, risk stratification, no unsupervised maxima), not the verdict [1][8].

The census column: the iceberg most of the file swims in

The second steadying receipt is the census. CARDIA — a coronary-risk cohort, not a clinic — obtained technically satisfactory echocardiograms on 4,111 men and women aged 23 to 35 drawn from the general population of four US cities, with no cardiac referral of any kind [7]. Result: probable or definite HCM in 7 subjects — 0.17%, "about 2 of 1000 young adults," prevalence higher in men (0.26%) than women (0.09%), septal thickness 15–21 mm (mean 17) in the seven [7]. The sentence that reshapes this whole door: "only 1 of the 7 subjects had ever experienced important cardiac symptoms attributable to HCM," had ever been suspected of cardiovascular disease, or had outflow obstruction — four others had only mild systolic anterior motion of the mitral valve that didn't obstruct [7]. Meanwhile five other subjects had equally thick walls caused by plain hypertension — the measurement alone doesn't diagnose, the workup does [7]. Two columns follow for the training reader. First, the iceberg shape: for every diagnosed reader walking into this door from a cardiology office, the wild population carries undiagnosed HCM through gyms every day, overwhelmingly without events — which is the observational base the new exercise era was built on [5][6][7]. Second, the symmetry of that fact: it cuts both ways — it means the untreated iceberg is real (the dismissive script's evidence) and it means the denominator of undiagnosed-but-training is enormous, so the registry's absolute rarity stands (the fear script's correction) [7][8]. The census column is why the answer here is a negotiated license rather than either a ban or a shrug [1].

The ban-era column: how the sport ban was written, and what it was written on

The reader who was told "no competitive sport, ever" was not lied to — she was quoted the 2015 consensus. The expert task forces of that era recommended that athletes with a probable or definite clinical diagnosis of HCM be excluded from most competitive sports, a position built to be conservative: with no exercise-training data in the disease, the abundance-of-caution logic treated the registry's 36% as reason enough [3]. What changed was not the risk — it was the evidence base. The 2018 turn, written by the cardiologist who would go on to run the exercise trial, is titled exactly what this door needed: "Exercise and Hypertrophic Cardiomyopathy: Time for a Change of Heart" — the observation that decades of restriction rested on expert opinion in the absence of data on exercise itself in HCM, while the harms of inactivity in the same patients were accumulating on the other side of the ledger [4]. Then the data arrived: the randomized trial [6], the observational exercise cohorts, the shared-decision programs — and by 2026 the European Heart Journal could write the paradigm paper this post is built around: individuals with HCM "have been systematically excluded from vigorous exercise and competitive sports… however, emerging evidence has challenged this paradigm," with improvements in functional capacity, quality of life and cardiovascular and psychological health "in the absence of safety signals" [5]. The ban-era column matters to the gym reader for a precise reason: a large fraction of the advice still circulating online is 2015-consensus reasoning quoted as if the trial era never happened [3][4][5]. The current documents — the 2024 AHA/ACC guideline describing HCM as "a common genetic heart disease reported in populations globally" managed with individualized, shared-decision counseling [1], and the 2020 ESC sports-cardiology guideline opening recreational moderate-intensity exercise for most patients [2] — are the ones her cardiologist is actually using.

The RCT column: 136 patients, 16 weeks, zero events

The single most load-bearing receipt in this file is the Michigan–Stanford randomized trial, because it is the thing the ban era said could not be run. Between 2010 and 2015 the investigators randomized 136 patients with HCM (mean age 50.4, 42% women) to 16 weeks of moderate-intensity exercise training or usual activity — 67 versus 69 — with exercise prescribed individually from baseline cardiopulmonary testing, structured like a cardiac-rehabilitation ladder rather than a bootcamp [6]. The primary outcome moved: peak oxygen consumption rose +1.35 mL/kg/min (95% CI 0.50–2.21) in the training group versus +0.08 (−0.62 to 0.79) in usual activity — a between-group difference of +1.27 (95% CI 0.17–2.37, P=.02), with 83% of participants completing the study [6]. And the safety sentence, quoted whole because every clause is the point: "there were no occurrences of sustained ventricular arrhythmia, sudden cardiac arrest, appropriate defibrillator shock, or death in either group" [6]. Honesty columns, as always in this library: the trial is described by its authors as preliminary — 16 weeks, 136 patients, powered for VO₂ not for rare events, and "moderate intensity" is the tested dose, not maximal sprint work [6]. But its direction is exactly what the systematic review would later pool: exercise as prescribed training in HCM was not producing the arrhythmia signal the 2015 caution assumed [4][6][12]. For the gym reader the translation is concrete: the tested program looks like the zone-2 base plus graduated moderate work her cardiologist can read off a rehab template — not a permission slip for unsupervised 1RM attempts [1][6].

The paradigm column: the door is open — with the low-risk key

The 2026 European Heart Journal review is the document that organizes everything above into the frame this post borrows: the shared decision. Its low-risk definition is the key that fits the newly open door: no high ESC sudden-death risk score, no exercise-induced syncope, no severe left-ventricular outflow tract obstruction, no ventricular arrhythmias [5]. For that subset, the review reads the pooled file as improved capacity and quality of life with tailored exercise — including competitive sports — "in the absence of safety signals," a position it describes as "becoming widely accepted internationally," with local regulatory differences [5]. For individuals who do not meet low-risk criteria, the review does not slam the door: participation "may still be considered on an individual basis" after risk-mitigation strategies — treatment of obstruction, ICD implantation where indicated — inside multidisciplinary counseling [5]. And the sentence that gives this post its title: the contemporary approach to HCM "should be based on individualized, goal-oriented exercise prescription, supported by multidisciplinary counselling and shared decision-making" [5]. Two columns follow for the training reader. First, the goal-orientation is literal: a powerlifter, a Hyrox amateur and a walker have different doors through the same diagnosis, and the prescription is written against her goals, not against a generic "cardiac patient" template [5]. Second, shared decision-making has a direction of travel — it is not "doctor googles with you"; it is the cardiologist bringing the measured risk file (echo, Holter, MRI, exercise test, family history [11]) and the patient bringing the training identity, and the two negotiating the actual brackets [1][5]. The reader who leaves that conversation with "moderate is cleared, maximums are fenced pending the exercise test" has a file she can train under — which is precisely what the older scripts never gave her [1][2][5].

The guideline column: what the governing documents now say

The floor under the paradigm paper is the guideline house. The 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline — the current US governing document for HCM, updating its 2020 predecessor — frames the disease as "a common genetic heart disease reported in populations globally" and manages the exercise question inside individualized counseling and shared decision-making rather than inside blanket exclusion [1]. The 2020 ESC sports-cardiology guideline sits on the European side of the same door: recreational moderate-intensity exercise is reasonable for most patients with HCM, while competitive-sport eligibility runs through individualized risk assessment — a graded license, not a ban and not a free pass [2]. Neither document claims the question is closed; both claim something more useful to this reader: the decision has an owner (her cardiologist, with her), a method (measured risk stratification), and a default (inactivity is not the default anymore — inactivity is itself a risk factor to be prescribed around) [1][2][5]. This is the column to bring to the family member who quotes the 1990s at the dinner table: the governing bodies that once wrote the exclusion now write the negotiation [1][2][3]. And for the reader who has not yet had the conversation, this column is the reason to schedule it: the guidance her cardiologist will use is five years old at most, and it assumes she wants to train [1][2].

The Brazilian column: the SBC's own 2026 review — 9,744 participants, no signal

The pt-BR twin of this door exists on unusually solid ground: the Brazilian Society of Cardiology published its own systematic review of exercise safety in HCM in 2026. The methods are the receipt: PubMed, Embase and Cochrane through December 2024; randomized and observational studies; 8 studies included — 4 RCTs and 4 observational, 9,744 participants — with RoB 2/ROBINS-I bias assessment, GRADE certainty, and recommendations written by an SBC expert panel [12]. The findings, in the review's own arithmetic: none of the studies reported increased mortality or severe arrhythmic events associated with physical exercise, "even at moderate or vigorous intensities"; syncope was rare; competitive sports in low-risk athletes were not associated with severe adverse events [12]. The dose–response column: a Korean observational cohort of more than 7,000 participants (mean age 59) showed all-cause mortality falling as physical-activity intensity rose [12]. The SBC's bottom line reads like the verdict of this entire file: physical exercise in HCM "should be encouraged based on individualized assessment," with benefits appearing to outweigh risks in patients without high-risk criteria for sudden death — and higher-risk subgroups counseled individually rather than excluded wholesale [12]. The honesty column: certainty of evidence ranged moderate to very low, exactly as an honest review of a rare-event question should report [12]. And the context column for the Brazilian reader: the SBC already mirrors the ESC screening scheme — clinical examination plus a 12-lead resting ECG for competitive athletes — while Brazilian sports medicine still lacks the genuinely national sudden-death registry its own authors have called for, which keeps the local denominator honest about its own uncertainty [13]. The Brazilian reader with HCM arrives at this door holding a document from her own country's cardiology society that says train — with individualized assessment [12][13].

The risk-marker column: what the cardiologist actually measures

The negotiation only works because the risk file is measurable, and the review that organizes the markers is the receipt. At rest, about a third of HCM patients have left-ventricular outflow tract obstruction, and it can be provoked in another third — the hemodynamic fact that gives the obstruction fence its physics [11]. The major risk markers for sudden death — the items the stratification actually scores — are nonsustained ventricular tachycardia on Holter, unexplained syncope, a family history of sudden cardiac death, and extreme hypertrophy, assembled by guideline risk calculators and balanced against the patient's age and the measured anatomy [11]. The avert-instrument: the implantable cardioverter-defibrillator, which "can usually avert" the sudden-death complication in appropriately selected high-risk patients — the reason a prior-arrest or sustained-VT history fences the format of training rather than ending it [11]. The genetics column: mutations in sarcomere-protein genes cause most HCM, MYH7 and MYBPC3 together accounting for roughly 50% of affected families, with the causal gene unidentified in about 40% of patients — which is why first-degree relatives are offered clinical screening (and, where the family mutation is known, targeted genetic testing), and why the genotype-positive but phenotype-negative relative is a surveillance patient, not a banned one [11]. The atrial fibrillation footnote: AF is a common complication and is poorly tolerated when it arrives — one more reason symptom honesty (a new irregular racing heart) routes to the cardiologist rather than to a deload [11]. The gym translation of this column is a checklist, not a vibe: her echo measures the wall and the outflow tract, her Holter counts the ventricular ectopy, her exercise test exposes what happens to her rhythm and pressures under load, her MRI maps fibrosis where indicated, and her family file prices the denominator — none of which lives inside a training log, and all of which the shared decision is written from [1][5][11].

The differentiation column: athlete's heart or HCM — the gray zone is a workup

This door's most confusing neighbor is its closest: the athlete's heart. Chronic intensive training remodels the heart — wall thickening, chamber enlargement — and the remodeling of a healthy athlete's heart overlaps the anatomy of mild HCM in the zone this post's third reader lives in: the gray boundary around 13–15 mm of septal wall, where physiology and disease share the measurement [10]. The differentiation file, as the classic review lays it out: athlete's-heart hypertrophy is typically symmetric, usually modest, accompanied by enlarged chambers, a physiologically adapted ECG pattern, and — the discriminating test many gym readers have never heard of — regresses with detraining, while HCM's hypertrophy is typically asymmetric, progresses, and does not regress when the training stops [10]. Around the overlap, the decision belongs to the full workup: echocardiography with assessment of the outflow tract, ECG interpreted against athlete-specific criteria, Holter, exercise testing, cardiac MRI for the gray-zone wall and the fibrosis map, and the family history and genetic file where the suspicion holds [10][11]. The column exists to discipline both scripts: the dismissive script reads "athlete, therefore athlete's heart" off a training log, and the fear script reads "17 mm, therefore HCM" off a report line — and the CARDIA census already showed how badly measurement alone performs, with five hypertensive subjects carrying walls as thick as the seven with HCM [7][10]. The gray-zone reader's program is honest and short: get the workup, and until it resolves, train inside the moderate brackets the trial era has cleared [1][6][10].

The mortality-trend column: the era the fear script was written in is over

The last column prices the air the fear script breathes. The US death-certificate file for 1999–2022 shows HCM-related age-adjusted mortality falling 53% cumulatively by 2019 (95% CI 50–56%) — against 25% for non-HCM cardiovascular disease and 18% for all causes — with the steepest declines among exactly the ages this door worries about: −62% among 15-to-24-year-olds (95% CI 47–73%) and −62% among 25-to-44-year-olds (95% CI 56–68%) [14]. The COVID interruption is priced honestly in the same file — HCM-related deaths rose 31% during the pandemic years, with an estimated 692 excess deaths — and the authors attribute the pre-pandine decline to the modern-management era: dedicated centers, risk stratification, ICDs in the high-risk, and treated obstruction [14]. For this reader the column does one precise job: the stadium-tragedy stories that populate her search results are drawn disproportionately from the registry decades [8][9], while the era she will actually train in is the one where the death rate in her age band has more than halved — which does not void the fences, and does retire the catastrophizing [14]. The training decades ahead of a newly diagnosed 25-year-old will be lived inside guideline care, measured risk files and an exercise prescription — not inside the 1980s registry [1][5][14].

The program in gym terms: what stops, what ramps, what never changes

Stops and refers, today: exertional fainting or near-fainting, exertional chest pain, breathlessness out of proportion, a new irregular racing heart, or a family history of sudden unexplained death before 50 — cardiology before the next session [1][8][11]; a prior cardiac arrest or sustained VT without a specialist plan — the specialist defines the bracket before anything maximal happens [11].

Ramps on measurements, not on feelings: the newly diagnosed reader trains moderate while the file is built — echo, Holter, exercise test, family screen [1][11]; the cleared reader earns intensity through the supervised exercise test that writes her actual brackets [2][5]; the competitive reader negotiates the door with the low-risk key — no high risk score, no exertional syncope, no severe obstruction, no ventricular arrhythmias — and if the key doesn't fit yet, the conversation is mitigation and ICD, not exile [5].

Doses the format around the obstruction physics: where the outflow tract obstructs — a third at rest, another third provokable [11] — the wrong session is a dehydrated morning maximal single with a long strained Valsalva; the right session is hydrated, warmed-up, moderate-loaded work with breathing discipline and rests that let the physiology settle, machine and tempo choices that avoid prolonged straining, and a warm-up ladder long enough to bring the wiring up with the plumbing [1][11].

Never changes: the overload principle applied inside her brackets, honest tracking of what each session actually felt like — the rep score and form check exist so effort is measured, not guessed — sensible set structure with rest timers, symmetry kept honest, sleep treated as cardiac infrastructure; the sick-day contract — fever and infection get rest, not sessions, because myocarditis is a different door in the same wing see the sick-day guide and the myocarditis audit; and the wider cardiac wing's doors for the readers whose files cross over — heart murmur, atrial fibrillation, heart failure, high blood pressure, the post-heart-attack comeback — with prevention for everyone else building the habit.

The bottom line

  • The registry column: HCM is the top cardiovascular cause of sudden death in young athletes — 36% of 1,049 cardiovascular deaths across 1,866 US athlete deaths, 82% during exertion, ~66 per year in the final registry years [8]; the update held 36%, 39% of male versus 11% of female deaths, 42% in Black versus 31% in white athletes [9].
  • The census column: CARDIA found HCM in 7 of 4,111 ordinary young adults (0.17%, "about 2 of 1000") — only 1 of the 7 ever symptomatic; five others had equally thick walls from hypertension alone [7].
  • The ban-era column: the 2015 task-force exclusion from most competitive sports [3] was written on accumulated expert caution, not exercise data — a fact the field itself named [4].
  • The RCT column: 136 patients, 16 weeks — VO₂peak +1.35 vs +0.08 mL/kg/min, between-group +1.27 (P=.02), and zero sustained ventricular arrhythmias, arrests, appropriate ICD shocks or deaths in either arm [6].
  • The paradigm column: 2026 EHJ — low-risk HCM (no high ESC risk score, no exertional syncope, no severe LVOT obstruction, no ventricular arrhythmias) can train and even compete "in the absence of safety signals"; others train on individual-basis mitigation; the frame is individualized, goal-oriented prescription and shared decision-making [5].
  • The guideline column: the 2024 AHA/ACC guideline [1] and the 2020 ESC sports-cardiology guideline [2] have replaced blanket bans with individualized exercise counseling.
  • The Brazilian column: the SBC's 2026 systematic review — 8 studies, 9,744 participants, zero mortality or severe-arrhythmia signal even at vigorous intensity, Korean dose–response mortality reduction, competitive sport clean in low-risk athletes, and exercise "should be encouraged based on individualized assessment" [12]; SBC mirrors ESC screening while Brazil still builds its national registry [13].
  • The risk-marker column: obstruction at rest in ~⅓ and provokable in another ⅓; the markers — NSVT, syncope, family history, extreme hypertrophy — measured by echo, Holter, exercise test, MRI; MYH7+MYBPC3 ≈ 50% of families; the ICD averts the complication in the high-risk [11].
  • The differentiation column: the 13–15 mm gray zone between symmetric, detraining-regressing athlete's heart and asymmetric, progressive HCM is resolved by the workup, not by a training log [10].
  • The mortality-trend column: US HCM mortality −53% from 1999 to 2019, −62% at ages 15–24 — the catastrophizing era is priced and retired [14].
  • The honest nulls: the RCT is preliminary and moderate-intensity-only [6]; the SBC review's certainty ranged moderate-to-very-low [12]; and no column in this file fences the diagnosed, stratified, low-risk reader out of training — the fences fence the unsupervised maximums, not the training life [1][5][12].

Train like the file reads: get the risk file measured once, negotiate the brackets honestly, and let the camera count the reps of the long game at rightrep.app.

This post was written by the RightRep AI Assistant — the same AI that counts and scores your reps at rightrep.app.

Sources

  1. Ommen SR, Mital S, Burke MA, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation, 2024;149(23):e1239–e1311. pubmed.ncbi.nlm.nih.gov
  2. Pelliccia A, Sharma S, Gati S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. European Heart Journal, 2021;42(1):17–96. pubmed.ncbi.nlm.nih.gov
  3. Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Myocarditis. Circulation, 2015;132(22):e273–e280. pubmed.ncbi.nlm.nih.gov
  4. Saberi S, Day SM. Exercise and Hypertrophic Cardiomyopathy: Time for a Change of Heart. Circulation, 2018;137(5):419–421. pubmed.ncbi.nlm.nih.gov
  5. Zampieri M, Spirito A, Autore C, et al. Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation. European Heart Journal, 2026;47(8):902–915. pubmed.ncbi.nlm.nih.gov
  6. Saberi S, Wheeler M, Bragg-Gresham J, et al. Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. JAMA, 2017;317(13):1349–1357. pubmed.ncbi.nlm.nih.gov
  7. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Circulation, 1995;92(4):785–789. pubmed.ncbi.nlm.nih.gov
  8. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation, 2009;119(8):1085–1092. pubmed.ncbi.nlm.nih.gov
  9. Maron BJ, Haas TS, Ahluwalia A, Murphy CJ, Garberich RF. Demographics and Epidemiology of Sudden Deaths in Young Competitive Athletes: From the United States National Registry. American Journal of Medicine, 2016;129(11):1170–1177. pubmed.ncbi.nlm.nih.gov
  10. Maron BJ, Pelliccia A. The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation, 2006;114(15):1633–1644. pubmed.ncbi.nlm.nih.gov
  11. Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Research, 2017;121(7):749–770. pubmed.ncbi.nlm.nih.gov
  12. Stein R, et al. Systematic Review on the Safety of Physical Exercise in Hypertrophic Cardiomyopathy: Recommendations from the Brazilian Society of Cardiology. Arquivos Brasileiros de Cardiologia, 2026;123(8):e20260423. pubmed.ncbi.nlm.nih.gov
  13. Helal L. Sudden Death in Young Brazilian Athletes: Isn't It Time We Created a Genuinely National Register? Arquivos Brasileiros de Cardiologia, 2018;111(6):856–859. pubmed.ncbi.nlm.nih.gov
  14. Sayed A, et al. Evidence of Declining Mortality Trends for Hypertrophic Cardiomyopathy in the United States and the Impact of the COVID-19 Pandemic. Journal of the American Heart Association, 2025;14(7):e037047. pubmed.ncbi.nlm.nih.gov